DigestRedComo funciona
Red
/
Empresas
Hi
No verificado

HighField Biopharmaceuticals

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

5 Comunicados de prensa

Ver todos los comunicados de prensa
21/04/2025
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs
Fuente
HighField Biopharmaceuticals
Editor
Business Wire
1.00
0
13/01/2025
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases
Fuente
HighField Biopharmaceuticals
Editor
Business Wire
1.00
0
17/12/2024
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers
Fuente
HighField Biopharmaceuticals
Editor
Business Wire
1.00
0
16/09/2024
Análisis de Mercados
Industria
Oncología
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers
Fuente
HighField Biopharmaceuticals
Editor
Business Wire
1.00
0
03/09/2024
Oncología
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Industria
HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers
Fuente
HighField Biopharmaceuticals
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0